Biomx Inc (PHGE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biomx Inc (PHGE) has a cash flow conversion efficiency ratio of -0.685x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.18 Million) by net assets ($10.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Biomx Inc (PHGE) market capitalisation for the company's overall valuation and market capitalisation.
Biomx Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Biomx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biomx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomx Inc ranked by their cash flow conversion efficiency. Explore PHGE cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Consolidated Firstfund Capital Corp
V:FFP
|
-0.029x |
|
Savoreat Ltd
TA:SVRT
|
-0.762x |
|
Xaar plc
LSE:XAR
|
-0.059x |
|
Golden Prospect Precious Metals Ltd
LSE:GPM
|
-0.016x |
|
Allurion Technologies, Inc.
NYSE:ALUR
|
0.041x |
|
MFC Industrial Real Estate Investment Trust
BK:MIT
|
-25.926x |
|
Baroyeca Gold & Silver Inc
V:BGS
|
0.194x |
|
Creative Eye Limited
NSE:CREATIVEYE
|
-0.116x |
Annual Cash Flow Conversion Efficiency for Biomx Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Biomx Inc from 2017 to 2024. View Biomx Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $24.15 Million | $-36.98 Million | -1.531x | +77.83% |
| 2023-12-31 | $3.08 Million | $-21.29 Million | -6.909x | -399.64% |
| 2022-12-31 | $21.04 Million | $-29.09 Million | -1.383x | -138.38% |
| 2021-12-31 | $47.53 Million | $-27.57 Million | -0.580x | -36.36% |
| 2020-12-31 | $57.47 Million | $-24.45 Million | -0.425x | -104.40% |
| 2019-12-31 | $84.46 Million | $-17.58 Million | -0.208x | +21.19% |
| 2018-12-31 | $42.80 Million | $-11.30 Million | -0.264x | +25.73% |
| 2017-12-31 | $11.53 Million | $-4.10 Million | -0.356x | -- |
About Biomx Inc
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic f… Read more